We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Irofulven Studied in Solid Tumors, Including Pancreatic Cancer

May 1, 2001
Volume: 
10
  • Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer

NEW YORK—Irofulven, the first of the acylfulvenes, a
new class of cytotoxic agents, is being studied in a number of solid tumors,
including a phase III trial in advanced pancreatic cancer, said Raymond Taetle,
MD, clinical professor of medicine and pathology, University of Arizona,
Arizona Cancer Center,
Tucson.

Irofulven, a semisynthetic derivative of Omphalotus olearius,
a
toxic fungus, has demonstrated broad activity against a range of solid tumor
cell lines in vitro. The agent, being developed by MGI Pharma, Minneapolis, is
also known as MGI 114 or hydroxymethylacylfulvene (HMAF).

Irofulven’s mechanism of action is not completely understood,
Dr. Taetle said in a presentation at the Chemotherapy Foundation Symposium
XVIII. Its antitumor activity appears to be independent of cellular p53 and p21
tumor-suppressor gene status.

"It demonstrates rapid cellular uptake, binding to
intracellular molecules, and potent and rapid inhibition of DNA
synthesis," he said. "The absence of cross resistance to a wide
variety of chemotherapy agents is promising. It is synergistic or additive in
combination with many other agents, notably topoisomerase 1 and 2
inhibitors."

In vitro response rates in surgically derived primary human
tumors of the colon, kidney, breast, lung, and ovary, as well as melanomas,
ranged from 41% to 83%. These results were obtained with tests using short-term
exposure at clinically relevant drug concentrations, Dr. Taetle said.

In vitro and in vivo studies of irofulven combined with other
agents showed additive and synergistic activity with platinum-based alkylating
agents, antimetabolites, tubulin binders (eg, taxanes), and gamma radiation, he
said.

Phase I trials showed a partial response in one patient with
refractory pancreatic cancer and stable disease in eight patients with
ampullary, colon, hepatocellular, renal cell, and thymic cancers.

Irofulven is currently being studied in phase II trials in
hormone-refractory prostate cancer, ovarian cancer, and hepatocellular
carcinoma, and has already shown activity in prostate and ovarian cancers, Dr.
Taetle said.

Side effects of irofulven include bone marrow suppression,
nausea and vomiting, and fatigue.

Randomized Multicenter Trial

A pivotal phase III trial of the agent has begun in patients
with advanced-stage pancreatic cancer whose disease progressed after treatment
with gemcitabine (Gemzar).

This randomized multicenter international trial compares
irofulven given in an intermittent, every-other-week dosing schedule (as a 10-
to 30-minute infusion) with fluorouracil given as a continuous IV infusion.
Daniel Von Hoff, MD, professor of medicine and director of the Arizona Cancer
Center, is the lead investigator of the study. The trial is expected to enroll
about 300 patients.

"The acylfulvenes are a highly potent new class of
chemotherapy agents," Dr. Taetle commented, citing its activity against a
broad range of resistant tumors and its potential synergy in combination
regimens.

Patients and health care providers seeking information on the
various irofulven clinical trials may call MGI Pharma’s Medical
Communications Help Line at 800-562-5580.

Related Articles

  • Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
  • Short-Acting CCBs May Increase Risk of Pancreatic Cancer
  • A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain
  • Deep Learning–Based Tissue Analysis May Benefit Colorectal Cancer Patients
  • Napabucasin May Be Effective in Colorectal Tumors Positive for pSTAT3

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.